Literature DB >> 25408831

Enantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective α4β2-nAChR Ligands.

Oluseye K Onajole1, J Brek Eaton2, Ronald J Lukas2, Dani Brunner3, Lucinda Thiede3, Barbara J Caldarone4, Alan P Kozikowski1.   

Abstract

We report the synthesis and characterization of a series of enantiopure 5-cyclopropane-bearing pyridyldiazabicyclo[3.3.0]octanes that display low nanomolar binding affinities and act as functional agonists at α4β2-nicotinic acetylcholine receptor (nAChR) subtype. Structure-activity relationship studies revealed that incorporation of a cyclopropane-containing side chain at the 5-position of the pyridine ring provides ligands with improved subtype selectivity for nAChR β2 subunit-containing nAChR subtypes (β2*-nAChRs) over β4*-nAChRs compared to the parent compound 4. Compound 15 exhibited subnanomolar binding affinity for α4β2- and α4β2*-nAChRs with negligible interaction. Functional assays confirm selectivity for α4β2-nAChRs. Furthermore, using the SmartCube assay system, this ligand showed antidepressant, anxiolytic, and antipsychotic features, while mouse forced-swim assay further confirm the antidepressant-like property of 15.

Entities:  

Keywords:  N-pyridyldiazabicyclo[3.3.0]octane; Nicotinic acetylcholine receptor; selective α4β2 partial agonist

Year:  2014        PMID: 25408831      PMCID: PMC4233362          DOI: 10.1021/ml500129k

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  30 in total

1.  Depression drug disappoints.

Authors:  Heidi Ledford
Journal:  Nature       Date:  2011-11-15       Impact factor: 49.962

Review 2.  Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature.

Authors:  Noah S Philip; Linda L Carpenter; Audrey R Tyrka; Lawrence H Price
Journal:  Psychopharmacology (Berl)       Date:  2010-07-08       Impact factor: 4.530

Review 3.  Central nicotinic receptors: structure, function, ligands, and therapeutic potential.

Authors:  M Novella Romanelli; Paola Gratteri; Luca Guandalini; Elisabetta Martini; Claudia Bonaccini; Fulvio Gualtieri
Journal:  ChemMedChem       Date:  2007-06       Impact factor: 3.466

4.  Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition.

Authors:  Hans Rollema; Mihály Hajós; Patricia A Seymour; Rouba Kozak; Mark J Majchrzak; Victor Guanowsky; Weldon E Horner; Doug S Chapin; William E Hoffmann; David E Johnson; Stafford McLean; Jody Freeman; Kathryn E Williams
Journal:  Biochem Pharmacol       Date:  2009-06-06       Impact factor: 5.858

Review 5.  Structural and functional diversity of native brain neuronal nicotinic receptors.

Authors:  Cecilia Gotti; Francesco Clementi; Alice Fornari; Annalisa Gaimarri; Stefania Guiducci; Irene Manfredi; Milena Moretti; Patrizia Pedrazzi; Luca Pucci; Michele Zoli
Journal:  Biochem Pharmacol       Date:  2009-05-27       Impact factor: 5.858

6.  Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior.

Authors:  Jill R Turner; Laura M Castellano; Julie A Blendy
Journal:  J Pharmacol Exp Ther       Date:  2010-04-30       Impact factor: 4.030

7.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

8.  Structure-activity studies of diazabicyclo[3.3.0]octane-substituted pyrazines and pyridines as potent α4β2 nicotinic acetylcholine receptor ligands.

Authors:  Marc J C Scanio; Lei Shi; William H Bunnelle; David J Anderson; Rosalind J Helfrich; John Malysz; Kirsten K Thorin-Hagene; Ceclia E Van Handel; Kennan C Marsh; Chih-Hung Lee; Murali Gopalakrishnan
Journal:  J Med Chem       Date:  2011-10-11       Impact factor: 7.446

9.  Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor.

Authors:  S C R Lummis; A J Thompson; M Bencherif; H A Lester
Journal:  J Pharmacol Exp Ther       Date:  2011-07-20       Impact factor: 4.030

10.  Insights into the structural determinants required for high-affinity binding of chiral cyclopropane-containing ligands to α4β2-nicotinic acetylcholine receptors: an integrated approach to behaviorally active nicotinic ligands.

Authors:  Han-Kun Zhang; J Brek Eaton; Li-Fang Yu; Mieke Nys; Angelica Mazzolari; René van Elk; August B Smit; Vadim Alexandrov; Taleen Hanania; Emily Sabath; Allison Fedolak; Daniela Brunner; Ronald J Lukas; Giulio Vistoli; Chris Ulens; Alan P Kozikowski
Journal:  J Med Chem       Date:  2012-09-07       Impact factor: 7.446

View more
  1 in total

1.  Synthesis and biological evaluation of novel hybrids of highly potent and selective α4β2-Nicotinic acetylcholine receptor (nAChR) partial agonists.

Authors:  Han-Kun Zhang; J Brek Eaton; Allison Fedolak; Hendra Gunosewoyo; Oluseye K Onajole; Dani Brunner; Ronald J Lukas; Li-Fang Yu; Alan P Kozikowski
Journal:  Eur J Med Chem       Date:  2016-09-09       Impact factor: 6.514

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.